Effects of dipeptidyl peptidase-4 inhibitors and sulphonylureas on cognitive and physical function in nursing home residents

by Berry, S.D, Dore, D.D, Duprey, M.S, Gutman, R., Munshi, M.N, Smith, R.J, Zullo, A.R
Published 2022

Defining Minimum Necessary Communication During Care Transitions for Patients on Antihyperglycemic Medication: Consensus of the Care Transitions Task Force of the IPRO Hypoglycemia...

by Florez, H.J, Huang, E.S, Lipska, K.J, Marcos Valencia, W., Munshi, M.N, Myrka, A., Sy, S.L, Triller, D.M, Yu, J.
Published 2022

Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy

by Branagan, A.R, Castillo, J.J, Flynn, C.A, Guerrera, M.L, Gustine, J.N, Hunter, Z.R, Kofides, A., Leventoff, C.R, Liu, X., Meid, K., Munshi, M., Patterson, C.J, Sarosiek, S.R, Treon, S.P, Tsakmaklis, N., White, T.P
Published 2022

Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia

by Branagan, A.R, Castillo, J.J, Demos, M.G, Flynn, C.A, Guerrera, M.L, Gustine, J.N, Hunter, Z.R, Kofides, A., Leventoff, C., Liu, X., Meid, K., Munshi, M., O’Donnell, E., Patterson, C.J, Raje, N., Sarosiek, S., Treon, S.P, Tsakmaklis, N., White, T., Xu, L., Yang, G., Yee, A.J
Published 2022

Venetoclax in Previously Treated Waldenström Macroglobulinemia

by Advani, R.H, Allan, J.N, Branagan, A.R, Castillo, J.J, Davids, M.S, Demos, M.G, Flynn, C.A, Furman, R.R, Guerrera, M.L, Hunter, Z.R, Kofides, A., Leventoff, C., Liu, X., Meid, K., Munshi, M., Patterson, C.J, Sarosiek, S., Siddiqi, T., Treon, S.P, Tsakmaklis, N., White, T.P, Xu, L., Yang, G.
Published 2022